Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06143956 | A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight | PHASE2 | RECRUITING | 1,481 | — | — | Nov 17, 2023 | Feb 1, 2028 | May 14, 2026 | 53 | United States, Argentina |
Each ISA will detail the intervention specific analysis.
| Arm | Type | Description |
|---|---|---|
| LY3305677 Obesity ISA OXA1 | EXPERIMENTAL | Participants will receive LY3305677 or placebo subcutaneously (SC). Each ISA will detail the intervention specific analysis. |
| LY3841136 Obesity ISA LAA1 | EXPERIMENTAL | Participants will receive LY3841136 or placebo SC. Each ISA will detail the intervention specific analysis. |
| LY3841136 Obesity ISA LAA2 | EXPERIMENTAL | Participants will receive LY3841136, tirzepatide and placebo SC. Each ISA will detail the intervention specific analysis. |
| LY3549492 Obesity ISA GN01 | EXPERIMENTAL | Participants will receive LY3549492 or placebo orally. Each ISA will detail the intervention specific analysis. |
| LY3549492 Obesity ISA GN02 | EXPERIMENTAL | Participants will receive LY3549492 or placebo orally. Each ISA will detail the intervention specific analysis. |
| Obesity ISA MC01 | EXPERIMENTAL | Participants will receive macupatide, eloralintide, and placebo SC. Each ISA will detail the intervention specific analysis. |
| Name | Type | Description |
|---|---|---|
| LY3305677 | DRUG | Administered SC. ISA specific interventions will be listed in the ISA. |
| LY3841136 | DRUG | Administered SC. ISA specific interventions will be listed in the ISA. |
| Tirzepatide | DRUG | Administered SC. ISA specific interventions will be listed in the ISA. |
| LY3549492 | DRUG | Administered orally. ISA specific interventions will be listed in the ISA. |
| LY3532226 | DRUG | Administered SC. ISA specific interventions will be listed in the ISA. |
| Placebo | DRUG | Administered SC. ISA specific interventions will be listed in the ISA. |
Inclusion Criteria: * Have a body mass index (BMI) * ≥30 kilogram/square meter (kg/m²), or * ≥27 kg/m² and \<30 kg/m², or with at least 1 weight-related comorbidity * Have had a stable body weight for the 3 months prior to randomization (\<5%) body weight gain and/or loss. Exclusion Criteria:...